TriangleHEALTH PROFESSIONAL · SOURCE READING
Loncastuximab tesirine
Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Loncastuximab tesirine is a CD19-directed antibody conjugated to a pyrrolobenzodiazepine dimer cytotoxin (an antibody-drug conjugate).[42]
Source links and citations
Evidence (loncastuximab tesirine):
A phase I and subsequent phase II trial included 184 patients with SCT-ineligible relapsed or refractory DLBCL after two or more lines of therapy.
A phase I and subsequent phase II trial included 184 patients with SCT-ineligible relapsed or refractory DLBCL after two or more lines of therapy.
The overall response rate was 48.3% (95% CI, 39.9%–56.7%), and the complete response rate was 24%.[43,44][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice